MAX Chat
Company Analysis Editas Medicine
1. Summary
Advantages
- Price (2.18 $) is less than fair price (3.23 $)
Disadvantages
- Dividends (0%) are below the sector average (0.527%).
- The stock's return over the last year (-42.93%) is lower than the sector average (-1.3%).
- Current debt level 10.26% has increased over 5 years from 5.72%.
- The company's current efficiency (ROE=-98.1%) is lower than the sector average (ROE=14.17%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Editas Medicine | Healthcare | Index | |
|---|---|---|---|
| 7 days | 14.1% | 9.1% | 1.2% |
| 90 days | 89.6% | 3.3% | 21.7% |
| 1 year | -42.9% | -1.3% | 21.8% |
EDIT vs Sector: Editas Medicine has significantly underperformed the "Healthcare" sector by -41.64% over the past year.
EDIT vs Market: Editas Medicine has significantly underperformed the market by -64.7% over the past year.
Slightly volatile price: EDIT is more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical deviations of about +/- 5-15% per week.
Long period: EDIT with weekly volatility of -0.8256% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (2.18 $) is lower than the fair price (3.23 $).
Price significantly below the fair price: The current price (2.18 $) is 48.2% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (64.15).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (90.03).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.7359) is lower than that of the sector as a whole (18.96).
P/BV vs Market: The company's P/BV (0.7359) is lower than that of the market as a whole (9.39).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (3.06) is lower than that of the sector as a whole (32.77).
P/S vs Market: The company's P/S indicator (3.06) is lower than that of the market as a whole (10.12).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.0099) is lower than that of the sector as a whole (274.79).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.0099) is lower than that of the market as a whole (50.91).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 30.88% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (30.88%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).
5.4. ROE
ROE vs Sector: The company's ROE (-98.1%) is lower than that of the sector as a whole (14.17%).
ROE vs Market: The company's ROE (-98.1%) is lower than that of the market as a whole (11.64%).
5.5. ROA
ROA vs Sector: The company's ROA (-56.4%) is lower than that of the sector as a whole (1.18%).
ROA vs Market: The company's ROA (-56.4%) is lower than that of the market as a whole (6.89%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-31.42%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-31.42%) is lower than that of the market as a whole (11.08%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.527%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
